MX2020006042A - Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. - Google Patents
Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas.Info
- Publication number
- MX2020006042A MX2020006042A MX2020006042A MX2020006042A MX2020006042A MX 2020006042 A MX2020006042 A MX 2020006042A MX 2020006042 A MX2020006042 A MX 2020006042A MX 2020006042 A MX2020006042 A MX 2020006042A MX 2020006042 A MX2020006042 A MX 2020006042A
- Authority
- MX
- Mexico
- Prior art keywords
- colon cancer
- mtor inhibitor
- methods
- combination therapy
- inhibitor combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente solicitud proporciona métodos para tratar un cáncer de colon (tal como el cáncer de colon avanzado y/o metastásico) en un individuo, que comprenden administrar al individuo: a) una cantidad efectiva de una composición que comprende nanopartículas que comprenden un inhibidor de Mtor (tal como un fármaco tipo limus, tal como sirolimus o un derivado del mismo) y una albúmina, b) una cantidad efectiva de anticuerpo anti-VEGF (tal como bevacizumab), y c) un régimen de FOLFOX terapéuticamente efectivo (tal como FOLFOX4 o un FOLFOX6 modificado).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762607798P | 2017-12-19 | 2017-12-19 | |
PCT/US2018/066309 WO2019126223A1 (en) | 2017-12-19 | 2018-12-18 | Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006042A true MX2020006042A (es) | 2020-10-20 |
Family
ID=66814095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006042A MX2020006042A (es) | 2017-12-19 | 2018-12-18 | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20190184031A1 (es) |
EP (1) | EP3727368A4 (es) |
JP (1) | JP2021506839A (es) |
KR (1) | KR20200101396A (es) |
CN (1) | CN111683657A (es) |
AU (1) | AU2018388579A1 (es) |
BR (1) | BR112020012060A2 (es) |
CA (1) | CA3084994A1 (es) |
EA (1) | EA202091514A1 (es) |
IL (1) | IL275261A (es) |
MX (1) | MX2020006042A (es) |
SG (1) | SG11202005613SA (es) |
WO (1) | WO2019126223A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2117520T (lt) | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
RS59322B1 (sr) | 2011-12-14 | 2019-10-31 | Abraxis Bioscience Llc | Upotreba polimernih ekscipijenata za liofilizaciju ili zamrzavanje partikula |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
KR20230165356A (ko) | 2015-06-29 | 2023-12-05 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
CA3094453A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
TW202123935A (zh) * | 2019-11-11 | 2021-07-01 | 美商亞伯辛生物科學有限責任公司 | 用於奈米粒子組合物之生物標記 |
JP2023500391A (ja) * | 2019-11-11 | 2023-01-05 | アブラクシス バイオサイエンス, エルエルシー | ナノ粒子組成物のためのバイオマーカー |
WO2022031630A1 (en) * | 2020-08-03 | 2022-02-10 | Oncocyte Corporation | Classifying tumors and predicting responsiveness |
CN113925975A (zh) * | 2021-08-31 | 2022-01-14 | 杭州师范大学 | p53及UTX信使RNA纳米粒的制备方法及该信使RNA的应用 |
WO2023150194A2 (en) * | 2022-02-02 | 2023-08-10 | Oncocyte Corporation | Classifying tumors and predicting responsiveness |
CN114702552A (zh) * | 2022-03-11 | 2022-07-05 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2481409T3 (en) * | 2007-03-07 | 2018-08-06 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
DE102011100122A1 (de) * | 2011-04-26 | 2012-10-31 | Eurocor Gmbh | Katheterballon beschichtet mit Rapamycin und Schellack |
AU2016287508B2 (en) * | 2015-06-29 | 2021-10-14 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy |
-
2018
- 2018-12-18 WO PCT/US2018/066309 patent/WO2019126223A1/en unknown
- 2018-12-18 CA CA3084994A patent/CA3084994A1/en active Pending
- 2018-12-18 JP JP2020533209A patent/JP2021506839A/ja active Pending
- 2018-12-18 SG SG11202005613SA patent/SG11202005613SA/en unknown
- 2018-12-18 EA EA202091514A patent/EA202091514A1/ru unknown
- 2018-12-18 MX MX2020006042A patent/MX2020006042A/es unknown
- 2018-12-18 KR KR1020207020473A patent/KR20200101396A/ko not_active Application Discontinuation
- 2018-12-18 BR BR112020012060-0A patent/BR112020012060A2/pt unknown
- 2018-12-18 EP EP18891945.0A patent/EP3727368A4/en active Pending
- 2018-12-18 CN CN201880088821.1A patent/CN111683657A/zh active Pending
- 2018-12-18 AU AU2018388579A patent/AU2018388579A1/en active Pending
- 2018-12-18 US US16/224,449 patent/US20190184031A1/en not_active Abandoned
-
2020
- 2020-06-10 IL IL275261A patent/IL275261A/en unknown
-
2023
- 2023-04-13 US US18/134,293 patent/US20240009323A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3084994A1 (en) | 2019-06-27 |
KR20200101396A (ko) | 2020-08-27 |
JP2021506839A (ja) | 2021-02-22 |
EA202091514A1 (ru) | 2020-09-15 |
WO2019126223A1 (en) | 2019-06-27 |
SG11202005613SA (en) | 2020-07-29 |
CN111683657A (zh) | 2020-09-18 |
AU2018388579A1 (en) | 2020-07-09 |
US20190184031A1 (en) | 2019-06-20 |
BR112020012060A2 (pt) | 2020-11-24 |
US20240009323A1 (en) | 2024-01-11 |
EP3727368A4 (en) | 2021-10-20 |
EP3727368A1 (en) | 2020-10-28 |
IL275261A (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
EA201890159A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
PH12018500642A1 (en) | Anti-garp antibody | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
IN2015DN00450A (es) | ||
ZA201907225B (en) | Treatment of her2 positive cancers | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
MX359770B (es) | Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r. | |
MX2019003694A (es) | Metodos para tratar cancer del tracto biliar. | |
JP2019532047A5 (es) | ||
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
WO2015035410A8 (en) | Cancer therapy | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
JP2014523421A5 (es) |